Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease and hepatocellular carcinoma worldwide. Approximately 350 million individuals are infected with HBV and >500,000 deaths per year can be attributed to HBV. Although universal vaccination has reduced HBV incidence in many countries, it still remains a major public health problem, especially in parts of Asia and Africa. Improved understanding of HBV virology and virus-host interactions has revolutionized chronic hepatitis B therapy in the past two decades. Development of oral nucleoside/nucleotide analogues heralds a new era of safe and effective treatment of this disease. On the basis of these advances, new guidelines for the treatment of chronic hepatitis B have been issued. Successful long-term treatment of chronic hepatitis B may rest on combination therapy that is based on molecular approaches targeting various stages of the HBV life-cycle. In this review, we summarize the current modalities and highlight important issues in the treatment of chronic hepatitis B monoinfection.
References
1.
KeeffeE.B., DieterichD.T., HanS.H.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update.Clin Gastroenterol Hepatol2006; 4: 936–962.
2.
ChenC.J., YangH.I., SuJ.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA.2006; 295: 65–73.
3.
GanemD., PrinceA.M.Hepatitis B virus infection - natural history and clinical consequences.N Engl J Med2004; 350: 1118–1129.
4.
ThioC.L.Diagnosis, diagnostic tests and monitoring of hepatitis B virus in monoinfected and HIV-coinfected patients.Antivir Ther2007; 12Suppl 3: H25–H31.
5.
MaS.Y., LauG.K., ChengV.C., LiangR.Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.Leuk Lymphoma2003; 44: 1281–1285.
6.
MindikogluA.L., RegevA., SchiffE.R.Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention.Clin Gastroenterol Hepatol2006; 4: 1076–1081.
7.
LauG.K., YiuH.H., FongD.Y.Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.Gastroenterology2003; 125: 1742–1749.
LiawY.F., LeungN., GuanR.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.Liver Int2005; 25: 472–489.
10.
HadziyannisS.J., PapatheodoridisG.V.Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment.Semin Liver Dis2006; 26: 130–141.
11.
WongD.K., CheungA.M., O'RourkeK., NaylorC.D., DetskyA.S., HeathcoteJ.Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis.Ann Intern Med1993; 119: 312–323.
12.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med2005; 352: 2682–2695.
13.
MarcellinP., LauG.K., BoninoF.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med2004; 351: 1206–1217.
14.
DienstagJ.L., SchiffE.R., WrightT.L.Lamivudine as initial treatment for chronic hepatitis B in the United States.N Engl J Med1999; 341: 1256–1263.
15.
LaiC.L., ChienR.N., LeungN.W.A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.N Engl J Med1998; 339: 61–68.
16.
MarcellinP., ChangT.T., LimS.G.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med2003; 348: 808–816.
17.
ChangT.T., GishR.G., de ManR.A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.N Engl J Med2006; 354: 1001–1010.
18.
LaiC.L., ShouvalD., LokA.S.Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.N Engl J Med2006; 354: 1011–1020.
19.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet2005; 365: 123–129.
20.
AndreoneP., CursaroC., GramenziA.A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody -and hepatitis B virus DNA - positive chronic hepatitis B.Hepatology1996; 24: 774–777.
21.
BrunettoM.R., OliveriF., ColombattoP., CapalboM., BarberaC., BoninoF.Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha.J Hepatol1995; 22Suppl 1: 42–44.
22.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med2003; 348: 800–807.
23.
HoofnagleJ.H., Di BisceglieA.M., WaggonerJ.G., ParkY.Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B.Gastroenterology1993; 104: 1116–1121.
24.
ErhardtA., BlondinD., HauckK., SagirA., KohnleT., HeintgesT., HaussingerD.Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.Gut2005; 54: 1009–1013.
25.
WaiC.T., ChuC.J., HussainM., LokA.S.HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.Hepatology2002; 36: 1425–1430.
26.
LoombaR., LiangT.J.Novel approaches to new therapies for hepatitis B virus infection.Antivir Ther2006; 11: 1–15.
27.
GaiaS., MarzanoA., SmedileA.Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.Aliment Pharmacol Ther2004; 20: 281–287.
28.
LeungN.W., LaiC.L., ChangT.T.Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.Hepatology2001; 33: 1527–1532.
29.
DienstagJ.L., GoldinR.D., HeathcoteE.J.Histological outcome during long-term lamivudine therapy.Gastroenterology2003; 124: 105–117.
30.
LiawY.F., SungJ.J.Y., ChowW.C.Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med2004; 351: 1521–1531.
31.
LokA.S., LaiC.L., LeungN.Long-term safety of lamivudine treatment in patients with chronic hepatitis B.Gastroenterology2003; 125: 1714–1722.
32.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.N Engl J Med2003; 348: 800–807.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.N Engl J Med2005; 352: 2673–2681.
35.
HadziyannisS.J., TassopoulosN.C., HeathcoteE.J.Long-term therapy with adefovir for HBeAg-negative chronic hepatitis B for up to 5 years.Gastroenterology2006; 131: 1743–1751.
36.
FungS.K., ChaeH.B., FontanaR.J.Virologic response and resistance to adefovir in patients with chronic hepatitis B.J Hepatol2006; 44: 283–290.
37.
YeonJ.E., YooW., HongS.P.Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil.Gut2006; 55: 1488–1495.
38.
FungS.K., AndreoneP., HanS.H., Rajender ReddyK., RegevA., KeeffeE.B., HussainM., CursaroC., RichtmyerP., MarreroJ.A., & LokA.S.Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.J Hepatol2005; 43: 937–943.
39.
ShermanM., YurdaydinC., SollanoJ.Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.Gastroenterology2006; 130: 2039–2049.
40.
GishR.C.T., De ManR., GadanoA.Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg (+) chronic hepatitis B patients (study ETV-022).Hepatology2005; 42: 267A.
41.
ChangT.T., ChaoY.C., KaymakagluS.Entecavir maintained virologic suppression through 3 years of treatment in antiviral naïve HBeAg(+) patients (ETV-022/019).Hepatology2006; 44Suppl 1: 229A.
42.
ColonnoR., LevineS., BaldickJ.Entecavir two year resistance update: No resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients.Hepatology2005; 42Suppl 1: 573A.
43.
ColonnoR., RoseC.E., PokornowskiK., BaldickJ., KlesczewskiK., TenneyD.Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients.Hepatology2006; 44Suppl 1: 229A.
44.
BryantM.L., BridgesE.G., PlacidiL.Antiviral L-nucleosides specific for hepatitis B virus infection.Antimicrob Agents Chemother2001; 45: 229–235.
45.
LaiC.L., LeungN., TeoE.K.A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B.Gastroenterology2005; 129: 528–536.
46.
LaiC.L., GaneE., LiawY.F.Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial.Hepatology2005; 42: 748A.
47.
LaiC.L., GaneE., HsuC-WTwo-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine.Hepatology2006; 44Suppl 1: 222A.
48.
van BommelF., WunscheT., MaussS.Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.Hepatology2004; 40: 1421–1425.
49.
van BommelF., ZollnerB., SarrazinC.Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.Hepatology2006; 44: 318–325.
50.
DietrichD.T.Special considerations and treatment of patients with HBV-HIV coinfection.Antivir Ther2007; 12Suppl 3: H43–H51.
51.
PetersM.G., HannH., MartinP.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology2004; 126: 91–101.
52.
RaptiI., DimouE., MitsoulaP., HadziyannisS.J.Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.Hepatology2007; 45: 307–313.
53.
WursthornK., LutgehetmannM., DandriM.Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.Hepatology2006; 44: 675–684.
54.
MarcellinP., AsselahT.Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.J Hepatol2005; 43: 920–923.
55.
CooksleyW.G.Treatment with interferons (including pegylated interferons) in patients with hepatitis B.Semin Liv Dis2004; 24Suppl 1: 45–53.
56.
ChienR.N., LiawY.F., AtkinsM.Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.Hepatology1999; 30: 770–774.
57.
van NunenA.B., HansenB.E., SuhD.J.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.Gut2003; 52: 420–424.
58.
MarxG., MartinS.R., ChicoineJ.F., AlvarezF.Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins.J Infect Dis2002; 186: 295–301.
